Novartis pelacarsen trial lowers lipoprotein(a) but fails to reduce heart events
Novartis released top-line results from its Phase 3 Lp(a) HORIZON trial earlier this month showing the drug lowered lipoprotein(a) levels without reducing cardiovascular events.
Trial outcomes for pelacarsen
The study demonstrated that pelacarsen successfully reduced levels of lipoprotein(a). Researchers noted the treatment did not move the needle on clinical outcomes. This result mirrors recent findings from Novo Nordisk's ZEUS trial regarding ziltivekimab.
Context of recent failures
The announcement follows a similar letdown involving an anti-inflammatory agent targeting IL-6. Both trials impacted their specific biological targets effectively. Neither intervention translated into fewer heart attacks or strokes for patients.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.